HEALTH
Rare Drug Makers Fight Medicare Price Caps
A biotech coalition is lobbying to keep 'orphan' drugs off the chopping block as federal price-cut pilots loom.
A coalition of biotech firms is pushing to exclude so-called 'orphan' drugs—treatments for rare diseases—from new Medicare price-cut pilot programs. The industry argues these exemptions are necessary to maintain research incentives, despite the federal push to lower overall drug costs.
- The Rare Disease Company Coalition is the primary group leading the lobbying effort.
- The target is to exclude orphan drugs from new federal pilot programs aimed at lowering Medicare spending.
- The initiative is part of broader industry efforts to navigate new federal price-capping strategies.
WHY THIS MATTERSIf these exemptions pass, Medicare continues to pay premium prices for specialized drugs, which keeps federal healthcare spending high. For you, this means the 'price-cut' promise of the current administration could be significantly diluted, leaving drug costs elevated.